adrecizumab
mAbexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started May 23, 2016 (NCT02991508)
Timeline
Indications
Mechanism of action
Adrenomedullin receptor AM1; CALCRL/RAMP2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- adrecizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05156671 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2021 | University of Hamburg |
| NCT04252937 | Phase 2 | Dec 15, 2019 | GREAT Network Italy |
| NCT03989531 | Phase 2/Phase 3 (Phase 3) | Apr 4, 2019 | University of Hamburg |
| NCT03085758 | Phase 2 | May 1, 2017 | Adrenomed AG |
| NCT03083171 | Phase 1 | Jan 4, 2017 | Adrenomed AG, Radboud University |
| NCT02991508 | Phase 1 | May 23, 2016 | Adrenomed AG, Radboud University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adrenomed AG | For profit | 3 | 2 | 2 | 2016 |
| Radboud University | Academic/Hospital | 2 | 1 | 1 | 2016 |
| University of Hamburg | Academic/Hospital | 2 | 2 | 1 | 2019 |
| GREAT Network Italy | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1